ClinicalTrials.gg
CompletedNCT02979535Updated Mar 25, 2022Results posted

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

A Phase 3 interventional study of CYD Dengue Vaccine and CYD Dengue Vaccine in Dengue Fever, Dengue Hemorrhagic Fever and Human Papillomavirus Disease, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 1 site in Mexico. Open to female participants aged 9 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.

Primary conditionSevere DengueRegistry: DengueReclassifiedWhy we changed it
Registry
Dengue — the first condition term the registry derived for this study.
ClinicalTrials.gg
Severe Dengue
Why
  1. The study's listed conditions name Severe Dengue, a narrower term within Dengue.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
9 Years to 14 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Severe Dengue by Sanofi — none open to participants now, none under way, none of them phase 3. Severe Dengue · Sanofi.

Enrollment
12th of 26
480 · median 345
Started
2016
with 6 others
Phase 3
9 of 29
none open now
Registered
27th of 29
by date

Among the 29 studies in Severe Dengue by Sanofi, this one is the 12th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2016, is one of 9 in phase 3, and was the 27th registered.

Severe Dengue

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

Browse Severe Dengue studies →

Open to participants now

None of the 29 studies in Severe Dengue by Sanofi is open now. The open studies under Severe Dengue, anywhere →

Who these studies take

Of the 4 Severe Dengue studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 9 Years to 14 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Severe Dengue by Sanofi as a file.
02

Study summary

The aim of this study was to investigate the immunogenicity and safety of CYD dengue vaccine and Cervarix when administered concomitantly or sequentially in healthy female participants aged 9-14 years of age.

Primary objectives:

  • To demonstrate that the humoral immune response (in terms of geometric mean titers [GMTs]) to Cervarix after concomitant administration with the CYD dengue vaccine is non-inferior to the humoral immune response (in terms of GMTs) after sequential administration with the CYD dengue vaccine measured 28 days after the last dose of Cervarix.
  • To demonstrate that the humoral immune response (in terms of GMTs) to the CYD dengue vaccine after concomitant administration with Cervarix is non-inferior to the humoral immune response (in terms of GMTs) to the CYD dengue vaccine after sequential administration with Cervarix measured 28 days after the last dose of the CYD dengue vaccine.

Secondary Objectives:

  • To demonstrate that the humoral immune response (in terms of seroconversion) to Cervarix after concomitant administration with the CYD dengue vaccine is non-inferior to the humoral immune response (in terms of seroconversion) to Cervarix sequential administration with the CYD dengue vaccine measured 28 days after the last dose of Cervarix.
  • To describe the humoral immune response to Cervarix at baseline and after each dose of Cervarix in each and any group.
  • To describe the humoral immune response to the CYD dengue vaccine at baseline and after each dose of the CYD dengue vaccine, in each and any group.
  • To describe the safety of Cervarix and CYD dengue vaccine after each and any dose in each group.
Read the detailed description

Participants received 3 doses of the CYD dengue vaccine and 2 doses of Cervarix administered either concomitantly or sequentially. Due to a protocol amendment, only previously dengue exposed participants (seropositive for dengue before vaccination) were eligible to complete the vaccination schedule and be assessed for CYD immunogenicity and human papilloma virus (HPV) immunogenicity. Dengue unexposed participants (seronegative for dengue before vaccination) did not receive the third CYD dengue vaccine injection, but were followed for safety up to 6 months after the last injection.

Safety assessments included solicited reactions within 7 or 14 days after each injection, unsolicited adverse events within 28 days after each injection, and serious adverse events during the study period. All participants were included in the assessment of safety up to 6 months after the last injection.

03

Conditions studied

  • Dengue Fever
  • Dengue Hemorrhagic Fever
  • Human Papillomavirus Disease

Browse trials for

Keywords

  • Dengue Fever
  • Dengue Hemorrhagic Fever
  • Human Papillomavirus Disease
  • CYD Dengue Vaccine
  • Dengvaxia®
  • Cervarix®
04

In context

Severe Dengue Reclassified

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

This study's enrollment of 480 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.

Browse Severe Dengue studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Severe Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dengue. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
9 Years to 14 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female aged 9 to 14 years (i.e., from the day of the 9th birthday to the day prior to the 15th birthday) on the day of inclusion.
  • form (ICF) or Assent form (AF) had been signed and dated by the participant (based on local regulations), and/or ICF had been signed and dated by the parent(s) or another legally acceptable representative (and by an independent witness if required by local regulations).
  • Participant (or participant and parent[s] or another legally acceptable representative) was (were) able to attend all scheduled visits and complied with all trial procedures.
  • Participant in good health, based on medical history, and physical examination.

Exclusion criteria

Exclusion Criteria:

  • Participant was pregnant, or lactating, or of (to be considered of non-childbearing potential, a female must be pre-menarche, surgically sterile, or using an effective method of or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination).
  • Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Planned receipt of any vaccine in the 4 weeks following any trial vaccination.
  • Previous vaccination against dengue disease with the trial vaccine.
  • Previous vaccination against HPV disease with either the trial vaccine or another vaccine.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency (including infection with impaired immune function); or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of HPV infection, confirmed either clinically, serologically, or microbiologically as reported by participant or parent(s) or another legally acceptable representative.
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
  • Thrombocytopenia, contraindicating IM vaccination.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction that, based on investigator's judgment, might interfere with the participant's ability to comply with trial procedures.
  • Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion.
  • Identified as an Investigator or employee of the Investigator with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
  • Self-reported , infection.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    CYD Dengue Vaccine + Cervarix (Concomitant Administration)

    Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.

    Biological: CYD Dengue Vaccine · Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant

  • Experimental
    CYD Dengue Vaccine + Cervarix (Sequential Administration)

    Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.

    Biological: CYD Dengue Vaccine · Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant

Interventions

07

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously Dengue Seropositive Participants

    GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an enzyme-linked immunosorbent assay (ELISA) method. Dengue seropositive participants at baseline were defined as those participants with titers greater than or equal to (\>=) 10 (1/dilutions \[dil\]) for at least one serotype with the parental dengue virus strain.

    Time frame: 28 days after the last Cervarix vaccination

  2. GMTs Against Each Dengue Virus Serotype 28 Days After the Third CYD Dengue Vaccination in the Previously Dengue Seropositive Participants

    The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

    Time frame: 28 days after third CYD dengue vaccination

Secondary outcomes

  1. GMTs Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) at Day 0 and 28 Days After Each Cervarix Vaccination in the Previously Dengue Seropositive Participants

    The GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

    Time frame: Day 0 and 28 days after each Cervarix vaccination

  2. Percentage of Participants With Seroconversion Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) 28 Days After Each Dose of Cervarix Vaccination in the Previously Dengue Seropositive Participants

    Neutralizing antibodies against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Seroconversion was defined as changing serostatus from seronegative at baseline to seropositive (greater than \[\>\] lower limit of quantitation \[LLOQ\] of the assay) or \>=4-fold rise in antibody titer if seropositive at baseline (i.e., at least one antibody levels against Cervarix HPV antigens \> LLOQ at baseline). The LLOQ for HPV-16 and HPV-18 was less than (\<) 2.0 International Units per milliliter (IU/mL).

    Time frame: 28 days after each Cervarix vaccination

  3. GMTs Against Each Dengue Virus Serotype of CYD Dengue Vaccine at Day 0 and 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants

    The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the PRNT50 assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

    Time frame: Day 0 and 28 days after each CYD dengue vaccine vaccination

  4. Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against Each of the 4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants

    Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

    Time frame: Day 0 and 28 days after each CYD dengue vaccine vaccination

  5. Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against At Least 1,2,3,or4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in Previously Dengue Seropositive Participants

    Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

    Time frame: Day 0 and 28 days after each CYD dengue vaccination

  6. Percentage of Participants With Neutralizing Antibody Titers Above Pre-defined Thresholds Against Each Dengue Virus Serotypes of CYD at Baseline And 28 Days After Each Dose of CYD Dengue Vaccination in Dengue Seropositive Participants

    Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\<10, \>=10 and \>=100 \[1/dil\]) against each dengue virus serotypes of CYD were reported.

    Time frame: Day 0 and 28 days after each CYD dengue vaccination

  7. Number of Participants Reporting Immediate Adverse Events (AEs) Following Vaccination With Cervarix or CYD Dengue Vaccine

    Any unsolicited systemic AE occurred during the first 30 minutes post-vaccination was recorded on the case report form (CRF) as immediate AE.

    Time frame: Within 30 minutes after each and any vaccination

  8. Number of Participants Reporting Solicited Injection Site Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine

    Solicited injection site reactions included pain, erythema, and swelling.

    Time frame: Up to 7 days after each and any vaccination

  9. Number of Participants Reporting Solicited Systemic Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine

    Solicited systemic reactions included Fever, Headache, Malaise, Myalgia, and Asthenia. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.

    Time frame: Up to 14 days after any and each vaccination

  10. Number of Participants Reporting Unsolicited AEs Following Vaccination With Cervarix or CYD Dengue Vaccine

    An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.

    Time frame: Up to 28 days after any and each vaccination

  11. Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Cervarix or CYD Dengue Vaccine

    AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.

    Time frame: Up to 7 days after any and each vaccination

  12. Number of Participants Reporting Serious Adverse Events (SAEs) Including Serious AESIs Following Vaccination With Cervarix or CYD Dengue Vaccine

    An SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. An AESIs were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.

    Time frame: From Day 0 up to 6 months after the last CYD or Cervarix vaccination

  13. Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Cervarix or CYD Dengue Vaccine

    Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.

    Time frame: From Day 0 up to 6 months after the last CYD or Cervarix vaccination

08

Results

Posted Mar 9, 2020
Limitations and caveats
Change of population for non-inferiority reduced to dengue seropositive participants and time window for vaccination not reached (study hold), hence non-inferiority analysis not performed \& immunogenicity analysis was performed on FAS \& not on PPS.

Participant flow

Study participants were enrolled from 16 November 2016 to 13 March 2017 at 3 centers in Mexico.

Participant flow — Overall Study
MilestoneCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Started239241
Safety analysis set237241
Completed144140
Not completed95101
Withdrew: Non compliance with the protocol7882
Withdrew: Consent withdrawn by participant1118
Withdrew: Lost to follow-up61

Outcome measures

PrimaryGeometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously Dengue Seropositive Participants

GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an enzyme-linked immunosorbent assay (ELISA) method. Dengue seropositive participants at baseline were defined as those participants with titers greater than or equal to (\>=) 10 (1/dilutions \[dil\]) for at least one serotype with the parental dengue virus strain.

Time frame:
28 days after the last Cervarix vaccination
Reported as:
Geometric mean · Endotoxin Units per milliliter (EU/mL)
Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously Dengue Seropositive Participants
Endotoxin Units per milliliter (EU/mL)CYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
HPV-162149 (1877 to 2460)2268 (1946 to 2644)
HPV-18833 (727 to 954)845 (723 to 987)
Statistical analysis
  • CYD Dengue Vaccine + Cervarix (Concomitant Administration) vs CYD Dengue Vaccine + Cervarix (Sequential Administration) · Gmt ratio: 0.947 · 95% CI 0.773 to 1.16
  • CYD Dengue Vaccine + Cervarix (Concomitant Administration) vs CYD Dengue Vaccine + Cervarix (Sequential Administration) · Gmt ratio: 0.986 · 95% CI 0.803 to 1.21
PrimaryGMTs Against Each Dengue Virus Serotype 28 Days After the Third CYD Dengue Vaccination in the Previously Dengue Seropositive Participants

The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the 50% plaque reduction neutralization test (PRNT50) assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

Time frame:
28 days after third CYD dengue vaccination
Reported as:
Geometric mean · titer (1/dilution)
GMTs Against Each Dengue Virus Serotype 28 Days After the Third CYD Dengue Vaccination in the Previously Dengue Seropositive Participants
titer (1/dilution)CYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Serotype 1384 (291 to 507)393 (292 to 528)
Serotype 2670 (535 to 839)735 (575 to 940)
Serotype 3357 (305 to 418)388 (325 to 463)
Serotype 4247 (213 to 287)265 (220 to 320)
Statistical analysis
  • CYD Dengue Vaccine + Cervarix (Concomitant Administration) vs CYD Dengue Vaccine + Cervarix (Sequential Administration) · Gmt ratio: 0.977 · 95% CI 0.653 to 1.46
  • CYD Dengue Vaccine + Cervarix (Concomitant Administration) vs CYD Dengue Vaccine + Cervarix (Sequential Administration) · Gmt ratio: 0.911 · 95% CI 0.654 to 1.27
  • CYD Dengue Vaccine + Cervarix (Concomitant Administration) vs CYD Dengue Vaccine + Cervarix (Sequential Administration) · Gmt ratio: 0.921 · 95% CI 0.727 to 1.17
  • CYD Dengue Vaccine + Cervarix (Concomitant Administration) vs CYD Dengue Vaccine + Cervarix (Sequential Administration) · Gmt ratio: 0.931 · 95% CI 0.733 to 1.18
SecondaryGMTs Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) at Day 0 and 28 Days After Each Cervarix Vaccination in the Previously Dengue Seropositive Participants

The GMTs against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

Time frame:
Day 0 and 28 days after each Cervarix vaccination
Reported as:
Geometric mean · EU/mL
GMTs Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) at Day 0 and 28 Days After Each Cervarix Vaccination in the Previously Dengue Seropositive Participants
EU/mLCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
HPV-16: Day 01.61 (1.31 to 1.97)1.58 (1.29 to 1.93)
HPV-16: 28 days post vaccination 1118 (98.7 to 142)140 (116 to 170)
HPV-16: 28 days post vaccination 22089 (1852 to 2356)2162 (1869 to 2501)
HPV-18: Day 01.34 (1.15 to 1.55)1.34 (1.16 to 1.54)
HPV-18: 28 days post vaccination 153.8 (44.1 to 65.7)68.6 (56.5 to 83.4)
HPV-18: 28 days post vaccination 2846 (752 to 951)846 (728 to 984)
SecondaryPercentage of Participants With Seroconversion Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) 28 Days After Each Dose of Cervarix Vaccination in the Previously Dengue Seropositive Participants

Neutralizing antibodies against each Cervarix HPV antigen (HPV-16 and HPV-18) were assessed using an ELISA method. Seroconversion was defined as changing serostatus from seronegative at baseline to seropositive (greater than \[\>\] lower limit of quantitation \[LLOQ\] of the assay) or \>=4-fold rise in antibody titer if seropositive at baseline (i.e., at least one antibody levels against Cervarix HPV antigens \> LLOQ at baseline). The LLOQ for HPV-16 and HPV-18 was less than (\<) 2.0 International Units per milliliter (IU/mL).

Time frame:
28 days after each Cervarix vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Seroconversion Against Each Cervarix HPV Antigen (HPV-16 and HPV-18) 28 Days After Each Dose of Cervarix Vaccination in the Previously Dengue Seropositive Participants
percentage of participantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
HPV-16: 28 days post-vaccination 198.0 (94.3 to 99.6)99.3 (96.4 to 100.0)
HPV-16: 28 days post-vaccination 298.7 (95.2 to 99.8)99.3 (96.3 to 100.0)
HPV-18: 28 days post-vaccination 1100.0 (97.6 to 100.0)98.7 (95.3 to 99.8)
HPV-18: 28 days post-vaccination 299.3 (96.3 to 100.0)100.0 (97.5 to 100.0)
SecondaryGMTs Against Each Dengue Virus Serotype of CYD Dengue Vaccine at Day 0 and 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants

The GMTs against each of the four parental dengue virus serotypes (Serotypes 1, 2, 3, and 4) of CYD dengue vaccine were assessed using the PRNT50 assay. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

Time frame:
Day 0 and 28 days after each CYD dengue vaccine vaccination
Reported as:
Geometric mean · titer (1/dilution)
GMTs Against Each Dengue Virus Serotype of CYD Dengue Vaccine at Day 0 and 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants
titer (1/dilution)CYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Serotype 1: Day 0150 (99.7 to 225)108 (72.1 to 163)
Serotype 1: 28 days post-vaccination 1711 (498 to 1016)586 (409 to 840)
Serotype 1: 28 days post-vaccination 2460 (336 to 630)476 (337 to 674)
Serotype 1: 28 days post-vaccination 3384 (291 to 507)393 (292 to 528)
Serotype 2: Day 0193 (141 to 263)188 (135 to 262)
Serotype 2: 28 days post-vaccination 11168 (879 to 1552)1163 (847 to 1597)
Serotype 2: 28 days post-vaccination 2618 (492 to 776)703 (541 to 913)
Serotype 2: 28 days post-vaccination 3670 (535 to 839)735 (575 to 940)
Serotype 3: Day 098.5 (72.2 to 135)90.2 (67.2 to 121)
Serotype 3: 28 days post-vaccination 1499 (386 to 644)503 (385 to 656)
Serotype 3: 28 days post-vaccination 2299 (251 to 358)361 (294 to 445)
Serotype 3: 28 days post-vaccination 3357 (305 to 418)388 (325 to 463)
Serotype 4: Day 047.1 (34.6 to 64.0)38.0 (28.4 to 50.9)
Serotype 4: 28 days post-vaccination 1423 (336 to 532)449 (365 to 552)
Serotype 4: 28 days post-vaccination 2267 (225 to 316)262 (219 to 314)
Serotype 4: 28 days post-vaccination 3247 (213 to 287)265 (220 to 320)
SecondaryPercentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against Each of the 4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants

Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

Time frame:
Day 0 and 28 days after each CYD dengue vaccine vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against Each of the 4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in the Previously Dengue Seropositive Participants
percentage of participantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Serotype 1: Day 074.0 (66.4 to 80.8)68.9 (60.8 to 76.2)
Serotype 1: 28 days post-vaccination 194.7 (89.8 to 97.7)95.3 (90.5 to 98.1)
Serotype 1: 28 days post-vaccination 297.3 (93.3 to 99.3)97.3 (93.1 to 99.2)
Serotype 1: 28 days post-vaccination 399.3 (96.2 to 100.0)97.9 (93.9 to 99.6)
Serotype 2: Day 092.9 (87.6 to 96.4)91.4 (85.7 to 95.3)
Serotype 2: 28 days post-vaccination 196.7 (92.4 to 98.9)93.9 (88.8 to 97.2)
Serotype 2: 28 days post-vaccination 2100.0 (97.6 to 100.0)98.6 (95.1 to 99.8)
Serotype 2: 28 days post-vaccination 3100.0 (97.5 to 100.0)100.0 (97.4 to 100.0)
Serotype 3: Day 082.5 (75.5 to 88.1)83.4 (76.5 to 89.0)
Serotype 3: 28 days post-vaccination 196.7 (92.4 to 98.9)96.6 (92.3 to 98.9)
Serotype 3: 28 days post-vaccination 299.3 (96.3 to 100.0)100.0 (97.5 to 100.0)
Serotype 3: 28 days post-vaccination 399.3 (96.2 to 100.0)100.0 (97.4 to 100.0)
Serotype 4: Day 068.8 (60.9 to 76.0)66.9 (58.8 to 74.3)
Serotype 4: 28 days post-vaccination 197.3 (93.3 to 99.3)98.6 (95.2 to 99.8)
Serotype 4: 28 days post-vaccination 2100.0 (97.6 to 100.0)100.0 (97.5 to 100.0)
Serotype 4: 28 days post-vaccination 3100.0 (97.5 to 100.0)98.6 (94.9 to 99.8)
SecondaryPercentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against At Least 1,2,3,or4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in Previously Dengue Seropositive Participants

Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain.

Time frame:
Day 0 and 28 days after each CYD dengue vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Neutralizing Antibody Titers >=10 (1/Dil) Against At Least 1,2,3,or4 Dengue Virus Serotypes of CYD Dengue Vaccine at Day 0 And 28 Days After Each Dose of CYD Dengue Vaccination in Previously Dengue Seropositive Participants
percentage of participantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
At least 1 Serotype: Day 0100.0 (97.6 to 100.0)100.0 (97.6 to 100.0)
At least 1 Serotype: 28 days post-vaccination 199.3 (96.3 to 100.0)99.3 (96.3 to 100.0)
At least 1 Serotype: 28 days post-vaccination 2100.0 (97.6 to 100.0)100.0 (97.5 to 100.0)
At least 1 Serotype: 28 days post-vaccination 3100.0 (97.5 to 100.0)100.0 (97.4 to 100.0)
At least 2 Serotype: Day 084.4 (77.7 to 89.8)82.8 (75.8 to 88.4)
At least 2 Serotype: 28 days post-vaccination 198.0 (94.3 to 99.6)98.0 (94.2 to 99.6)
At least 2 Serotype: 28 days post-vaccination 2100.0 (97.6 to 100.0)100.0 (97.5 to 100.0)
At least 2 Serotype: 28 days post-vaccination 3100.0 (97.5 to 100.0)100.0 (97.4 to 100.0)
At least 3 Serotype: Day 074.0 (66.4 to 80.8)72.8 (65.0 to 79.8)
At least 3 Serotype: 28 days post-vaccination 195.3 (90.6 to 98.1)94.6 (89.6 to 97.6)
At least 3 Serotype: 28 days post-vaccination 299.3 (96.3 to 100.0)98.6 (95.1 to 99.8)
At least 3 Serotype: 28 days post-vaccination 3100.0 (97.5 to 100.0)98.6 (94.9 to 99.8)
All 4 Serotypes: Day 059.7 (51.5 to 67.6)55.0 (46.7 to 63.1)
All 4 Serotypes: 28 days post-vaccination 192.7 (87.3 to 96.3)92.6 (87.1 to 96.2)
All 4 Serotypes: 28 days post-vaccination 297.3 (93.3 to 99.3)97.3 (93.1 to 99.2)
All 4 Serotypes: 28 days post-vaccination 398.6 (95.0 to 99.8)97.9 (93.9 to 99.6)
SecondaryPercentage of Participants With Neutralizing Antibody Titers Above Pre-defined Thresholds Against Each Dengue Virus Serotypes of CYD at Baseline And 28 Days After Each Dose of CYD Dengue Vaccination in Dengue Seropositive Participants

Dengue neutralizing antibody levels against each of the 4 dengue virus serotypes (Serotypes 1, 2, 3, and 4) were measured by PRNT50. Dengue seropositive participants at baseline were defined as those participants with titers \>=10 (1/dil) for at least one serotype with the parental dengue virus strain. Percentage of participants with neutralizing antibody titers above pre-defined thresholds (\<10, \>=10 and \>=100 \[1/dil\]) against each dengue virus serotypes of CYD were reported.

Time frame:
Day 0 and 28 days after each CYD dengue vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Neutralizing Antibody Titers Above Pre-defined Thresholds Against Each Dengue Virus Serotypes of CYD at Baseline And 28 Days After Each Dose of CYD Dengue Vaccination in Dengue Seropositive Participants
percentage of participantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Serotype 1: Pre-vaccination 1 <10 (1/dil)26.0 (19.2 to 33.6)31.1 (23.8 to 39.2)
Serotype 1: Pre-vaccination 1 >=10 (1/dil)74.0 (66.4 to 80.8)68.9 (60.8 to 76.2)
Serotype 1: Pre-vaccination 1 >=100 (1/dil)61.0 (52.9 to 68.8)56.3 (48.0 to 64.3)
Serotype 1: Post-vaccination 1 <10 (1/dil)5.3 (2.3 to 10.2)4.7 (1.9 to 9.5)
Serotype 1: Post-vaccination 1 >=10 (1/dil)94.7 (89.8 to 97.7)95.3 (90.5 to 98.1)
Serotype 1: Post-vaccination 1 >=100 (1/dil)82.0 (74.9 to 87.8)78.4 (70.9 to 84.7)
Serotype 1: Post-vaccination 2 <10 (1/dil)2.7 (0.7 to 6.7)2.7 (0.8 to 6.9)
Serotype 1: Post-vaccination 2 >=10 (1/dil)97.3 (93.3 to 99.3)97.3 (93.1 to 99.2)
Serotype 1: Post-vaccination 2 >=100 (1/dil)77.2 (69.6 to 83.7)72.6 (64.6 to 79.7)
Serotype 1: Post-vaccination 3 <10 (1/dil)0.7 (0.0 to 3.8)2.1 (0.4 to 6.1)
Serotype 1: Post-vaccination 3 >=10 (1/dil)99.3 (96.2 to 100.0)97.9 (93.9 to 99.6)
Serotype 1: Post-vaccination 3 >=100 (1/dil)74.8 (66.9 to 81.7)76.4 (68.5 to 83.2)
Serotype 2: Pre-vaccination 1 <10 (1/dil)7.1 (3.6 to 12.4)8.6 (4.7 to 14.3)
Serotype 2: Pre-vaccination 1 >=10 (1/dil)92.9 (87.6 to 96.4)91.4 (85.7 to 95.3)
Serotype 2: Pre-vaccination 1 >=100 (1/dil)59.1 (50.9 to 66.9)61.6 (53.3 to 69.4)
Serotype 2: Post-vaccination 1 <10 (1/dil)3.3 (1.1 to 7.6)6.1 (2.8 to 11.2)
Serotype 2: Post-vaccination 1 >=10 (1/dil)96.7 (92.4 to 98.9)93.9 (88.8 to 97.2)
Serotype 2: Post-vaccination 1 >=100 (1/dil)91.3 (85.6 to 95.3)91.9 (86.3 to 95.7)
Serotype 2: Post-vaccination 2 <10 (1/dil)0.0 (0.0 to 2.4)1.4 (0.2 to 4.9)
Serotype 2: Post-vaccination 2 >=10 (1/dil)100.0 (97.6 to 100.0)98.6 (95.1 to 99.8)
Serotype 2: Post-vaccination 2 >=100 (1/dil)90.6 (84.7 to 94.8)90.4 (84.4 to 94.7)
Serotype 2: Post-vaccination 3 <10 (1/dil)0.0 (0.0 to 2.5)0.0 (0.0 to 2.6)
Serotype 2: Post-vaccination 3 >=10 (1/dil)100.0 (97.5 to 100.0)100.0 (97.4 to 100.0)
Serotype 2: Post-vaccination 3 >=100 (1/dil)95.1 (90.2 to 98.0)90.7 (84.6 to 95.0)
Serotype 3: Pre-vaccination 1 <10 (1/dil)17.5 (11.9 to 24.5)16.6 (11.0 to 23.5)
Serotype 3: Pre-vaccination 1 >=10 (1/dil)82.5 (75.5 to 88.1)83.4 (76.5 to 89.0)
Serotype 3: Pre-vaccination 1 >=100 (1/dil)51.3 (43.1 to 59.4)49.0 (40.8 to 57.3)
Serotype 3: Post-vaccination 1 <10 (1/dil)3.3 (1.1 to 7.6)3.4 (1.1 to 7.7)
Serotype 3: Post-vaccination 1 >=10 (1/dil)96.7 (92.4 to 98.9)96.6 (92.3 to 98.9)
Serotype 3: Post-vaccination 1 >=100 (1/dil)88.7 (82.5 to 93.3)87.8 (81.5 to 92.6)
Serotype 3: Post-vaccination 2 <10 (1/dil)0.7 (0.0 to 3.7)0.0 (0.0 to 2.5)
Serotype 3: Post-vaccination 2 >=10 (1/dil)99.3 (96.3 to 100.0)100.0 (97.5 to 100.0)
Serotype 3: Post-vaccination 2 >=100 (1/dil)87.2 (80.8 to 92.1)87.0 (80.4 to 92.0)
Serotype 3: Post-vaccination 3 <10 (1/dil)0.7 (0.0 to 3.8)0.0 (0.0 to 2.6)
Serotype 3: Post-vaccination 3 >=10 (1/dil)99.3 (96.2 to 100.0)100.0 (97.4 to 100.0)
Serotype 3: Post-vaccination 3 >=100 (1/dil)94.4 (89.3 to 97.6)90.7 (84.6 to 95.0)
Serotype 4: Pre-vaccination 1 <10 (1/dil)31.2 (24.0 to 39.1)33.1 (25.7 to 41.2)
Serotype 4: Pre-vaccination 1 >=10 (1/dil)68.8 (60.9 to 76.0)66.9 (58.8 to 74.3)
Serotype 4: Pre-vaccination 1 >=100 (1/dil)33.1 (25.8 to 41.1)29.8 (22.6 to 37.8)
Serotype 4: Post-vaccination 1 <10 (1/dil)2.7 (0.7 to 6.7)1.4 (0.2 to 4.8)
Serotype 4: Post-vaccination 1 >=10 (1/dil)97.3 (93.3 to 99.3)98.6 (95.2 to 99.8)
Serotype 4: Post-vaccination 1 >=100 (1/dil)87.3 (80.9 to 92.2)89.9 (83.8 to 94.2)
Serotype 4: Post-vaccination 2 <10 (1/dil)0.0 (0.0 to 2.4)0.0 (0.0 to 2.5)
Serotype 4: Post-vaccination 2 >=10 (1/dil)100.0 (97.6 to 100.0)100.0 (97.5 to 100.0)
Serotype 4: Post-vaccination 2 >=100 (1/dil)82.6 (75.5 to 88.3)80.1 (72.7 to 86.3)
Serotype 4: Post-vaccination 3 <10 (1/dil)0.0 (0.0 to 2.5)1.4 (0.2 to 5.1)
Serotype 4: Post-vaccination 3 >=10 (1/dil)100.0 (97.5 to 100.0)98.6 (94.9 to 99.8)
Serotype 4: Post-vaccination 3 >=100 (1/dil)83.2 (76.1 to 88.9)83.6 (76.4 to 89.3)
SecondaryNumber of Participants Reporting Immediate Adverse Events (AEs) Following Vaccination With Cervarix or CYD Dengue Vaccine

Any unsolicited systemic AE occurred during the first 30 minutes post-vaccination was recorded on the case report form (CRF) as immediate AE.

Time frame:
Within 30 minutes after each and any vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Immediate Adverse Events (AEs) Following Vaccination With Cervarix or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
After any CYD/Cervarix vaccination00
Post CYD/Cervarix vaccination 100
Post CYD/Cervarix vaccination 200
Post CYD vaccination 300
SecondaryNumber of Participants Reporting Solicited Injection Site Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine

Solicited injection site reactions included pain, erythema, and swelling.

Time frame:
Up to 7 days after each and any vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Injection Site Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Pain: Post any CYD/Cervarix vaccine212221
Pain: Post CYD/Cervarix vaccination 1202206
Pain: Post CYD/Cervarix vaccination 2173169
Pain: Post CYD vaccination 36559
Erythema: Post any CYD/Cervarix vaccine6461
Erythema: Post CYD/Cervarix vaccination 14943
Erythema: Post CYD/Cervarix vaccination 24134
Erythema: Post CYD vaccination 3611
Swelling: Post any CYD/Cervarix vaccine7360
Swelling: Post CYD/Cervarix vaccination 15544
Swelling: Post CYD/Cervarix vaccination 24835
Swelling: Post CYD vaccination 3810
SecondaryNumber of Participants Reporting Solicited Systemic Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine

Solicited systemic reactions included Fever, Headache, Malaise, Myalgia, and Asthenia. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.

Time frame:
Up to 14 days after any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Systemic Reactions Following Vaccination With Cervarix or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Fever: Post any vaccination2535
Fever: Post vaccination 1 (Visit 1)148
Fever: Post CYD vaccination 1 (Visit 2)—14
Fever: Post vaccination 2 (Visit 4)1012
Fever: Post CYD vaccination 2 (Visit 5)—8
Fever: Post CYD vaccination 3 (Visit 7)53
Headache: Post any vaccination101111
Headache: Post vaccination 1 (Visit 1)8369
Headache: Post CYD vaccination 1 (Visit 2)—54
Headache: Post vaccination 2 (Visit 4)4748
Headache: Post CYD vaccination 2 (Visit 5)—36
Headache: Post CYD vaccination 3 (Visit 7)1815
Malaise: Post any vaccination113133
Malaise: Post vaccination 1 (Visit 1)8484
Malaise: Post CYD vaccination 1 (Visit 2)—56
Malaise: Post vaccination 2 (Visit 4)7372
Malaise: Post CYD vaccination 2 (Visit 5)—47
Malaise: Post CYD vaccination 3 (Visit 7)1928
Myalgia: Post any vaccination160168
Myalgia: Post vaccination 1 (Visit 1)129124
Myalgia: Post CYD vaccination 1 (Visit 2)—76
Myalgia: Post vaccination 2 (Visit 4)9695
Myalgia: Post CYD vaccination 2 (Visit 5)—60
Myalgia: Post CYD vaccination 3 (Visit 7)2631
Asthenia: Post any vaccination9395
Asthenia: Post vaccination 1 (Visit 1)7253
Asthenia: Post CYD vaccination 1 (Visit 2)—47
Asthenia: Post vaccination 2 (Visit 4)5135
Asthenia: Post CYD vaccination 2 (Visit 5)—30
Asthenia: Post CYD vaccination 3 (Visit 7)1613
SecondaryNumber of Participants Reporting Unsolicited AEs Following Vaccination With Cervarix or CYD Dengue Vaccine

An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination. At Visit 1 and Visit 4, participants from Group 1 received both Cervarix and CYD vaccination and participants from Group 2 received only Cervarix vaccination. At Visit 2 and Visit 5, only participants from Group 2 received CYD vaccination whereas the participants from Group 1 received no vaccination.

Time frame:
Up to 28 days after any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Unsolicited AEs Following Vaccination With Cervarix or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Post any vaccination5076
Post vaccination 1 (Visit 1)3337
Post CYD vaccination 1 (Visit 2)—25
Post vaccination 2 (Visit 4)2623
Post CYD vaccination 2 (Visit 5)—15
Post CYD vaccination 3 (Visit 7)55
SecondaryNumber of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Cervarix or CYD Dengue Vaccine

AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.

Time frame:
Up to 7 days after any and each vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Non-serious Adverse Event of Special Interests (AESIs) Following Vaccination With Cervarix or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Post any CYD/Cervarix vaccination00
Post CYD/Cervarix vaccination 100
Post CYD/Cervarix vaccination 200
Post CYD/Cervarix vaccination 300
SecondaryNumber of Participants Reporting Serious Adverse Events (SAEs) Including Serious AESIs Following Vaccination With Cervarix or CYD Dengue Vaccine

An SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event. An AESIs were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.

Time frame:
From Day 0 up to 6 months after the last CYD or Cervarix vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Serious Adverse Events (SAEs) Including Serious AESIs Following Vaccination With Cervarix or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
SAE60
Serious AESI00
SecondaryNumber of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Cervarix or CYD Dengue Vaccine

Hospitalized suspected dengue case was defined as an acute febrile illness with diagnosis of dengue requiring hospitalization (with bed attribution). In such cases, 1 unplanned acute blood sample (within the first 5 days after fever onset) was collected for virological confirmation of hospitalized suspected dengue case. A suspected case was considered VCD if there was a detection of wild type dengue virus by dengue non-structural protein 1 antigen ELISA and/or dengue reverse transcriptase-polymerase chain reactions.

Time frame:
From Day 0 up to 6 months after the last CYD or Cervarix vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Cervarix or CYD Dengue Vaccine
ParticipantsCYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)
Number of Participants Reporting Cases of Virologically Confirmed Dengue (VCD) Hospitalization Following Vaccination With Cervarix or CYD Dengue Vaccine00

Adverse events

Collected over AE data were collected from Day 0 up to Day 28 post any vaccination. Solicited Reaction (SR) were collected from Day 0 up to Day 14 post vaccination. The SAEs were collected throughout the trial (up to Month 14), i.e,. 6 months after last CYD vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CYD Dengue Vaccine + Cervarix (Sequential Administration)0/237 (0%)6/237 (2.5%)222/237 (93.7%)
CYD Dengue Vaccine + Cervarix (Concomitant Administration)0/241 (0%)0/241 (0%)228/241 (94.6%)
Most frequent serious events
Most frequent serious events
EventCYD Dengue Vaccine + Cervarix (Sequential Administration)CYD Dengue Vaccine + Cervarix (Concomitant Administration)
AppendicitisInfections and infestations1/2370/241
Forearm FractureInjury, poisoning and procedural complications1/2370/241
Gun Shot WoundInjury, poisoning and procedural complications1/2370/241
Radius FractureInjury, poisoning and procedural complications1/2370/241
Pre-EclampsiaPregnancy, puerperium and perinatal conditions1/2370/241
NephrolithiasisRenal and urinary disorders1/2370/241
Most frequent other events
Most frequent other events
EventCYD Dengue Vaccine + Cervarix (Sequential Administration)CYD Dengue Vaccine + Cervarix (Concomitant Administration)
Injection Site PainGeneral disorders212/237221/241
MyalgiaMusculoskeletal and connective tissue disorders160/237168/241
MalaiseGeneral disorders113/237133/241
HeadacheNervous system disorders102/237113/241
AstheniaGeneral disorders93/23795/241
Injection Site SwellingGeneral disorders73/23760/241
Injection Site ErythemaGeneral disorders64/23761/241
PyrexiaGeneral disorders25/23737/241
NasopharyngitisInfections and infestations8/23722/241
PharyngitisInfections and infestations13/23720/241

Baseline characteristics

Baseline characteristics were analyzed on all randomized population which included participants for whom an injection group were allocated.

Age, Continuous
Age, Continuous(years)CYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)Total
Mean9.50 ± 1.009.56 ± 1.059.53 ± 1.03
Sex: Female, Male
Sex: Female, Male(Participants)CYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)Total
Female239241480
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CYD Dengue Vaccine + Cervarix (Concomitant Administration)CYD Dengue Vaccine + Cervarix (Sequential Administration)Total
Race: Not reported239241480
09

Study locations

1 site
  • Mexico City, Mexico
10

References and documents

Publications

  • Arredondo JL, Villagomez Martinez SM, Concepcion Morales M, Meyer S, Toh ML, Zocchetti C, Vigne C, Mascarenas C. Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico. Vaccine. 2021 Jun 8;39(25):3388-3396. doi: 10.1016/j.vaccine.2021.04.064. Epub 2021 May 13. PubMed 33992441 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Mar 2019, 28 months.

Results were first posted in Mar 2020, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2016
First posted
Dec 1, 2016
StartActual
Nov 16, 2016
Primary completionActual
Mar 25, 2019
CompletionActual
Mar 25, 2019
Results first posted
Mar 9, 2020
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02979535
Responsible party
Sponsor
First posted
Dec 1, 2016
Start date
Nov 16, 2016
Primary completion
Mar 25, 2019
Completion
Mar 25, 2019
Results posted
Mar 9, 2020
Last update
Mar 25, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur SA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human papillomavirus vaccine, L1 type 16, 18

Start the discussion